The BLA was submitted in light of positive data yielded from a phase 2/3 clinical study.
The breakthrough status was granted in light of positive results of phase 1/2 clinical study.
This activity aims to sharpen clinical knowledge and skills relating to the nursing role in eradication of inhibitory antibodies to factor VIII and IX via ITI therapy.
If effective, the therapy prompts the sustained production of FVIII and enhanced protection from bleeds.
Four leading bleeding disorders organizations joint together to endorse the bipartisan Alexander-Murray Market Stabilization bill.
The National Hemophilia Foundation (NHF) has announced the launch of a new research project focusing on the benefits of genetic counseling using telemedicine (telegenetics) for carriers of hemophilia.
UniQure announced plans to “expeditiously advance” its investigational hemophilia B gene therapy AMT-061 into a study in 2018.
Researchers have made an important discovery that could change the way doctors understand and treat inhibitor development in hemophilia A
Actions from the President adds uncertainty to the health insurance market.
Michael Kuklish is the recipient of the 2017 Kevin Child Scholarship.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car